Semaglutide and Papillary Thyroid Carcinoma: Current Evidence on Risk, Progression, and Mechanisms

Studied

A narrative review examined semaglutide and papillary thyroid cancer, including cancer development, progression and laboratory mechanisms.

Who / model

Evidence included 93 trials with 101,732 participants and a cohort of 1072 people with existing differentiated thyroid cancer, followed for a median 69 months.

Studied dose & schedule

Dose and schedule have not yet been extracted for this summary.

Found

The reviewed trials showed no statistically clear increase in thyroid-cancer risk. The existing-cancer cohort found no association with structural progression. Other observational and adverse-report analyses raised risk signals.

Limits

Detection bias and obesity-related confounding affect the risk signals. Further prospective research specific to cancer subtype is needed.

Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary